BioVie Inc. (NASDAQ:BIVI) Sees Significant Decline in Short Interest

BioVie Inc. (NASDAQ:BIVI) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 44.0% from the December 31st total of 2,090,000 shares. Based on an average daily volume of 6,120,000 shares, the short-interest ratio is currently 0.2 days.

BioVie Trading Down 3.5 %

NASDAQ BIVI traded down $0.06 during trading on Thursday, hitting $1.67. 401,604 shares of the company traded hands, compared to its average volume of 1,004,126. The business has a fifty day simple moving average of $2.38 and a 200 day simple moving average of $2.20. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10. The company has a market capitalization of $29.67 million, a P/E ratio of -0.15 and a beta of 0.49.

Institutional Investors Weigh In On BioVie

An institutional investor recently bought a new position in BioVie stock. Sanders Morris Harris LLC purchased a new stake in BioVie Inc. (NASDAQ:BIVI) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 40,000 shares of the company’s stock, valued at approximately $85,000. Sanders Morris Harris LLC owned approximately 0.23% of BioVie at the end of the most recent reporting period. 4.59% of the stock is owned by institutional investors and hedge funds.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.